// App-Quantinova.ai

246 : Safety and effectiveness of certolizumab pegol in axial spodyloarthritis in a real-world setting: a UK sub-analysis from a European non-interventional study

Researchers

Presenter

  • Helena Marzo-Ortega

Principal Investigators

  • Raj Sengupta

  • Nicola Goodson

  • Pauline Ho

  • Kirsten Mackay

  • Bengt Hoepken

  • Brenda Van Lunen

  • Xenofon Baraliakos

Medical Centers

  • Department of Rheumatology, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath, UNITED KINGDOM

  • Haematology Department, Aintree University Hospital NHS Foundation Trust, Liverpool

  • The Kellgren Centre, Manchester University Foundation Trust, Manchester, UNITED KINGDOM

  • Rheumatology, Torbay and South Devon NHS Foundation Trust, Torbay, UNITED KINGDOM

  • Clinical Program Director, UCB Pharma, Monheim am Rhein, GERMANY

  • Principal Biostatistician, UCB Pharma, Raleigh, NC

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

Locations

  • United Kingdom

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Axial spondyloarthritis

Biomarkers

  • Cluster of differentiation 95

  • Complement Factor B

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Non Interventional

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT02354105

Sponsors

  • National Institute for Health and Care Research

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved